PURPOSE: This study attempted to compare changes in the Quality-of-Life (QoL) scores after three different first-line anti- @entity5 treatments for advanced @entity1149 ( @entity1149 ) in a real-world clinical setting. @entity1 AND METHODS: From May 2011 to December 2013, we prospectively measured the QoL scores of @entity1 with locally advanced or metastatic @entity1149 using the World Health Organization Quality-of-Life-Brief (WHOQOL-BREF) questionnaire. Each QoL measurement was matched by age and sex with one healthy referent from the National Health Interview Survey. Dynamic changes in @entity1 ' QoL scores and major determinants were repeatedly assessed by construction of a mixed-effects model to adjust for possible confounders. RESULTS: A total of 336 @entity1 with 577 QoL measurements related to first-line anti- @entity5 treatments were enrolled. Performance status was the most important predictor of QoL scores in all domains after controlling for potential confounders. With age- and sex-matched healthy subjects as the reference, @entity1 treated with @entity136  +  @entity902 showed significantly lower scores in multiple physical and psychological domain items in the WHOQOL-BREF. However, pemetrexed  +  @entity902 and @entity4562 / @entity3866 affected @entity1 ' QoL scores in 'energy/fatigue' and 'daily activities' with smaller magnitudes, and the scores appeared to improve after 3-4  months of treatment. CONCLUSIONS: @entity1 receiving @entity136  +  @entity902 as first-line anti- @entity5 treatment for advanced @entity1149 experienced relatively poor QoL scores throughout treatment course. Studies to develop a real-time computerized system automatically updating the mixed-effects model for QoL to facilitate participatory clinical decision making by physicians, @entity1 , and their families merit further research.

Health-related quality of life after first-line anti- XXXX treatments for advanced @entity1149 in clinical practice.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
